LifeStance Health Group (NASDAQ:LFST) Announces Earnings Results, Beats Estimates By $0.02 EPS

LifeStance Health Group (NASDAQ:LFST) released its earnings results on Thursday. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02, Zacks reports. The company had revenue of $455.86 million during the quarter, compared to the consensus estimate of $431.59 million. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. LifeStance Health Group’s quarterly revenue was up 25.3% on a year-over-year basis.

Here are the key takeaways from LifeStance Health Group’s conference call:

• Third-quarter revenue rose 25% to $456 million, driven by 17% growth in visit volume and a 7% increase in revenue per visit. Adjusted EBITDA increased 70% to $68 million, a 15% margin for the second consecutive quarter.
• LifeStance raised its full-year 2026 guidance: revenue to $1.741 billion–$1.761 billion and Adjusted EBITDA to $242 million–$250 million. The midpoint implies 23% revenue growth and roughly 300 basis points of year-over-year margin expansion.
• The clinician base grew 11% to 8,863, with 321 net additions in the quarter; management cited strong recruiting and stable retention. Visits per average clinician rose 5% year over year, which executives attributed partly to improved patient engagement.
• Specialty services revenue is expected to grow about 40% in 2026 to roughly $70 million, with management expecting a similar growth rate next year. The company is gradually expanding TMS and SPRAVATO, while citing positive outcomes data and opportunities to discuss coverage and reimbursement with payers.
• The new EHR rollout is expected to reduce 2027 revenue growth by approximately 1–2 percentage points, putting growth toward the lower end of LifeStance’s long-term mid-teens range. Management also previously estimated implementation costs of $20 million–$30 million; the phased rollout is expected to be completed by year-end 2027.

LifeStance Health Group Stock Up 2.5%

NASDAQ LFST traded up $0.34 on Friday, hitting $13.77. 4,924,487 shares of the stock were exchanged, compared to its average volume of 3,459,394. LifeStance Health Group has a fifty-two week low of $5.87 and a fifty-two week high of $15.66. The company has a 50-day moving average price of $12.62 and a 200-day moving average price of $9.49. The company has a quick ratio of 1.38, a current ratio of 1.44 and a debt-to-equity ratio of 0.17. The company has a market cap of $5.26 billion, a PE ratio of 72.47 and a beta of 1.35.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
• Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

Analyst Ratings Changes

Several brokerages have recently issued reports on LFST. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Wall Street Zen cut shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Canaccord Genuity Group upped their target price on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. increased their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $13.75.

Insider Activity

In related news, COO Lisa K. Miller sold 47,912 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the completion of the transaction, the chief operating officer directly owned 281,289 shares of the company’s stock, valued at $3,051,985.65. This represents a 14.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the completion of the transaction, the insider owned 98,101,407 shares in the company, valued at $1,041,836,942.34. This represents a 12.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 13,777,580 shares of company stock worth $146,433,781. 3.50% of the stock is currently owned by insiders.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.